Patents Assigned to NEUMEDICINES INC.
-
Publication number: 20180207237Abstract: Provided are formulations for proteins to be injected into mammals. Specifically, formulations for recombinant IL-12 in mice and primates.Type: ApplicationFiled: January 26, 2018Publication date: July 26, 2018Applicant: Neumedicines, Inc.Inventor: Lena A. Basile
-
Patent number: 9925246Abstract: The present application relates to treatment of cutaneous wounds using IL-12. The methods of the invention result in improved wound closure. The methods comprise treating cutaneous wounds using topical, subcutaneous, and/or intramuscular administration of IL-12.Type: GrantFiled: June 13, 2012Date of Patent: March 27, 2018Assignee: NEUMEDICINES, INC.Inventors: Lena A. Basile, Dolph Ellefson, Timothy K. Gallaher
-
Patent number: 9878012Abstract: Provided are formulations for proteins to be injected into mammals. Specifically, formulations for recombinant IL-12 in mice and primates.Type: GrantFiled: May 18, 2011Date of Patent: January 30, 2018Assignee: Neumedicines, Inc.Inventor: Lena A. Basile
-
Patent number: 9636381Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced toxicity associated with the treatment of cutaneous T-cell lymphoma.Type: GrantFiled: January 18, 2013Date of Patent: May 2, 2017Assignee: NEUMEDICINES, INC.Inventor: Lena A. Basile
-
Patent number: 9616106Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced toxicity associated with the treatment of cutaneous T-cell lymphoma.Type: GrantFiled: January 18, 2013Date of Patent: April 11, 2017Assignee: Neumedicines, Inc.Inventor: Lena A. Basile
-
Patent number: 9463219Abstract: The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.Type: GrantFiled: April 14, 2014Date of Patent: October 11, 2016Assignee: NEUMEDICINES, INC.Inventor: Lena A. Basile
-
Publication number: 20160120948Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for improving hematopoietic recovery HSCT transplantation in a subject. In particular, the instant disclosure provide exemplary methods and compositions comprising IL-12 promoted hematopoiesis and increased the recovery of peripheral blood cells and survival in lethally irradiated mice as effectively as a BMCT, indicating that rHuIL-12 therapy can to increase HSC engraftment following HSCT. We identified IL-12R?2 expressing cells in irradiated mouse bone marrow which are potential targets of IL-12. Administration of rMuIL-12 increased the number of IL-12R?2 expressing Lin? cells in mouse bone marrow, indicating that bone marrow HSCs and niche cells are the direct target of rMuIL-12 and that hematopoiesis-promoting activity of rMuIL-12 is mediated by IL-12 receptors on HSCs.Type: ApplicationFiled: October 30, 2015Publication date: May 5, 2016Applicant: Neumedicines, Inc.Inventor: Lena A. BASILE
-
Publication number: 20160120949Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) as a hematopoietic immunotherapy (HIT) useful for treating or preventing a cancer patient from chemotherapy-induced cytopenias necessitating a dose reduction and/or dose delay. following exposure of the patient to chemotherapeutic agents, the method comprising: administering a dose of therapeutically effective amount of a pharmaceutical composition comprising substantially isolated IL-12 to the subject, whereby cytopenias are reduced and leading to increases responses to the chemotherapy agent(s).diminished.Type: ApplicationFiled: October 30, 2015Publication date: May 5, 2016Applicant: NEUMEDICINES, INC.Inventor: Lena A. BASILE
-
Publication number: 20160045569Abstract: The present invention is directed to an endogenous vaccine targeted to a cancer or an infectious disease.Type: ApplicationFiled: March 13, 2014Publication date: February 18, 2016Applicant: Neumedicines, Inc.Inventor: Lena A. Basile
-
Publication number: 20150343021Abstract: The present application relates to methods of treating cancer using compositions comprising Hematopoietic Signal peptide-containing Secreted 1 (HSS1), derivatives of HSS1. Hematopoietic Signal peptide-containing Membrane domain-containing 1 (HSM1), derivatives of HSM1, or any combination thereof.Type: ApplicationFiled: May 29, 2015Publication date: December 3, 2015Applicant: Neumedicines, Inc.Inventors: Lena A. Basile, Christopher Edward Lawrence
-
Publication number: 20150147294Abstract: The present invention provides methods for increasing survival in a subject, and/or preserving bone marrow function, and/or promoting hematopoietic recovery or restoration. The methods include administering a dose of IL-12 to the subject following an acute exposure to non-therapeutic whole body ionizing radiation. Formulations and kits are also provided.Type: ApplicationFiled: December 19, 2014Publication date: May 28, 2015Applicant: Neumedicines, Inc.Inventor: Lena A. Basile
-
Publication number: 20150110739Abstract: The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells.Type: ApplicationFiled: August 26, 2014Publication date: April 23, 2015Applicant: NEUMEDICINES, INC.Inventor: Lena A. BASILE
-
Patent number: 8962317Abstract: The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells.Type: GrantFiled: September 27, 2011Date of Patent: February 24, 2015Assignee: Neumedicines, Inc.Inventor: Lena A. Basile
-
Patent number: 8921315Abstract: The present invention provides methods for increasing survival in a subject, and/or preserving bone marrow function, and/or promoting hematopoietic recovery or restoration. The methods include administering a dose of IL-12 to the subject following an acute exposure to non-therapeutic whole body ionizing radiation. Formulations and kits are also provided.Type: GrantFiled: April 24, 2009Date of Patent: December 30, 2014Assignee: Neumedicines, Inc.Inventor: Lena A. Basile
-
Publication number: 20140369958Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising inter-leukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced toxicity associated with the treatment of cutaneous T-cell lymphoma.Type: ApplicationFiled: January 18, 2013Publication date: December 18, 2014Applicant: Neumedicines, Inc.Inventor: Lena A. Basile
-
Publication number: 20140342995Abstract: The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.Type: ApplicationFiled: April 14, 2014Publication date: November 20, 2014Applicant: Neumedicines, Inc.Inventor: Lena A. BASILE
-
Patent number: 8846392Abstract: The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells.Type: GrantFiled: September 27, 2011Date of Patent: September 30, 2014Assignee: Neumedicines, Inc.Inventors: Lena A. Basile, Timothy Kirk Gallaher
-
Patent number: 8735342Abstract: The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.Type: GrantFiled: January 27, 2011Date of Patent: May 27, 2014Assignee: Neumedicines, Inc.Inventor: Lena A. Basile
-
Publication number: 20130259828Abstract: The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells.Type: ApplicationFiled: September 27, 2011Publication date: October 3, 2013Applicant: NEUMEDICINES, INC.Inventors: Lena A. Basile, Timothy Kirk Gallaher
-
Publication number: 20130243722Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced toxicity associated with the treatment of cutaneous T-cell lymphoma.Type: ApplicationFiled: January 18, 2013Publication date: September 19, 2013Applicant: NEUMEDICINES INC.Inventors: Lena Basile, Timothy K. Gallaher, Dolph D. Ellefson